Washington Square-based biotech company Vivodyne raised $38 million in its quest to develop lab-grown human organs.
Khosla Ventures led the round. Kairos Ventures, CS Ventures, MBX Capital and Bison Ventures also participated. The company is calling the raise “seed funding,” though the average seed round is more like $3.6 million.
Vivodyne uses robotic automation to test drugs on over 20 types of lab-grown human organ tissue. The company’s platform sets therapeutic targets and predicts patient responses to new drugs, with a goal of speeding the success of clinical trials.
READ FULL ARTICLE HERE
